CytomX Therapeutics, Inc.
CTMX
$2.98
$0.041.36%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -75.91% | -44.82% | -10.26% | 18.01% | 23.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -75.91% | -44.82% | -10.26% | 18.01% | 23.81% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -75.91% | -44.82% | -10.26% | 18.01% | 23.81% |
| SG&A Expenses | -4.46% | -3.33% | -11.99% | -3.77% | 5.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.72% | -15.33% | -24.62% | -13.94% | 3.00% |
| Operating Income | -272.02% | -178.28% | 246.44% | 653.67% | 232.15% |
| Income Before Tax | -240.79% | -153.38% | 87.67% | 219.88% | 104.35% |
| Income Tax Expenses | -0.85% | 6.28% | -80.08% | -93.79% | -94.01% |
| Earnings from Continuing Operations | -242.16% | -154.50% | 102.59% | 332.83% | 151.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -242.16% | -154.50% | 102.59% | 332.83% | 151.64% |
| EBIT | -272.02% | -178.28% | 246.44% | 653.67% | 232.15% |
| EBITDA | -261.02% | -167.96% | 186.81% | 486.76% | 192.43% |
| EPS Basic | -175.80% | -97.70% | 138.57% | 301.66% | 141.21% |
| Normalized Basic EPS | -167.96% | -88.25% | 120.28% | 197.87% | 95.16% |
| EPS Diluted | -177.32% | -99.01% | 143.38% | 316.39% | 146.64% |
| Normalized Diluted EPS | -167.98% | -88.21% | 121.82% | 199.83% | 96.10% |
| Average Basic Shares Outstanding | 86.98% | 63.11% | 39.99% | 17.57% | 10.29% |
| Average Diluted Shares Outstanding | 86.90% | 62.77% | 39.70% | 17.30% | 10.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |